CN112021566A - Dendrobium officinale, American ginseng and radix ophiopogonis granules - Google Patents
Dendrobium officinale, American ginseng and radix ophiopogonis granules Download PDFInfo
- Publication number
- CN112021566A CN112021566A CN202010834915.8A CN202010834915A CN112021566A CN 112021566 A CN112021566 A CN 112021566A CN 202010834915 A CN202010834915 A CN 202010834915A CN 112021566 A CN112021566 A CN 112021566A
- Authority
- CN
- China
- Prior art keywords
- parts
- dendrobium officinale
- american ginseng
- radix ophiopogonis
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000005373 Panax quinquefolius Species 0.000 title claims abstract description 41
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 41
- 241001076416 Dendrobium tosaense Species 0.000 title claims abstract description 40
- 239000008187 granular material Substances 0.000 title claims abstract description 37
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 7
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 7
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 7
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 33
- 230000036039 immunity Effects 0.000 abstract description 18
- 230000002708 enhancing effect Effects 0.000 abstract description 14
- 230000036541 health Effects 0.000 abstract description 7
- 235000006533 astragalus Nutrition 0.000 abstract description 6
- 235000013402 health food Nutrition 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 238000000605 extraction Methods 0.000 description 25
- 238000001914 filtration Methods 0.000 description 25
- 239000007788 liquid Substances 0.000 description 25
- 238000005086 pumping Methods 0.000 description 25
- 238000009835 boiling Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 238000005303 weighing Methods 0.000 description 13
- 244000248557 Ophiopogon japonicus Species 0.000 description 12
- 230000000242 pagocytic effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 229930195210 Ophiopogon Natural products 0.000 description 8
- 206010057249 Phagocytosis Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 230000008782 phagocytosis Effects 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 231100000039 Ames test Toxicity 0.000 description 7
- 238000010953 Ames test Methods 0.000 description 6
- 239000005913 Maltodextrin Substances 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000811 xylitol Substances 0.000 description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 6
- 229960002675 xylitol Drugs 0.000 description 6
- 235000010447 xylitol Nutrition 0.000 description 6
- 241000045403 Astragalus propinquus Species 0.000 description 5
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 5
- 238000011047 acute toxicity test Methods 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 238000013112 stability test Methods 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000036244 malformation Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010050208 Teratospermia Diseases 0.000 description 3
- 208000002312 Teratozoospermia Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000146029 Lindera aggregata Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- -1 moisture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 231100000204 oral acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses dendrobium officinale, radix ophiopogonis and American ginseng granules, which comprise the following components in parts by weight: 10-40 parts of dendrobium officinale, 10-40 parts of American ginseng and 10-40 parts of radix ophiopogonis, and in addition, any one or more of 1-10 parts of astragalus, 1-10 parts of Chinese yam and 1-10 parts of rhizoma polygonati can be further included, and the raw materials are extracted, concentrated and granulated to prepare granules. The traditional Chinese medicine health food is developed on the basis of the traditional Chinese medicine health care and health preserving theory, has scientific and reasonable formula, simple preparation process, safety, stability and effectiveness, has the function of enhancing immunity, and is suitable for people with low immunity to take.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine health products, in particular to a traditional Chinese medicine granule which is composed of a plurality of traditional Chinese medicines such as dendrobium officinale, American ginseng, dwarf lilyturf tuber and the like and has the function of enhancing immunity.
Background
The modern society enters the era of high-speed operation and intense competition, fast-paced life, high-pressure work and study often make people have irregular life, improper work and improper diet, and the immunologic function of the organism is easy to decline. With the development of the times, the understanding of human beings on the health concept is further deepened along with the development of the technological level, and according to the research findings of more than 50 national medical experts of the world health organization, the best treatment and prevention of various diseases are realized. At present, the examination of various hospitals can only diagnose the generated diseases, once the diseases are confirmed, the patients are still stranded too late, and even though the modern medical science and technology means are used, the patients are difficult to recover as before. The book Huangdi's classic on medicine has a speech: the method is characterized in that the method adopts corresponding measures to prevent the disease from happening and developing and is the main idea of the traditional Chinese medicine. Any disease can be prevented and maintained first, the incidence of the disease is very low, and even the disease can be completely solved and avoided. The most important means for preventing diseases is to enhance the immunity of the organism.
The functional localization of health foods and the health care needs of different people, the current description of health care functions only for enhancing immunity may not meet the requirements of people using the foods. Under the guidance of the theory of traditional Chinese medicine, the same discomfortable performance, different regions, constitutions and inducements can greatly differ from one another, for example, the similar malady performance is the performance of easily catching cold due to low immunity, and the different constitutions and inducements (in vivo damp heat, blood stasis and the like) can be caused by different crowds (old people, children and people with weak constitution), and the different causes can be respectively selected when the health food for enhancing immunity is taken, for example, the crowd with excessive heat in the body should not select a product with ginseng as a main raw material.
How to develop a universal health food with the function of enhancing immunity is a difficult problem to be solved by the society and enterprises at present.
Disclosure of Invention
The invention aims to provide dendrobium officinale, radix ophiopogonis and American ginseng granules aiming at the existing problems.
The purpose of the invention is realized by the following technical scheme: a dendrobium officinale, radix ophiopogonis and American ginseng granule comprises the following components in parts by weight: 10-40 parts of dendrobium officinale, 10-40 parts of radix ophiopogonis and 10-40 parts of American ginseng. In addition, any one or more of astragalus root 1-10 parts, Chinese yam 1-10 parts and sealwort 1-10 parts may be included.
Animal efficacy experiments are carried out by using the dendrobium officinale, ophiopogon root and American ginseng granules:
the immunity enhancing experiment is provided with three dosage groups, namely a low dosage group, a medium dosage group and a high dosage group, which are respectively equal to 5, 10 and 30 times of the actual intake of a human, and the mice are gavaged and are provided with a negative control group (deionized water). Different doses of test samples were orally administered for 30-31 consecutive days. The experimental results show that: compared with a control group, the optical density difference of the lymphocyte proliferation capacity of the mice in the medium and high dose groups is increased, the anti-volume numerical value of hemolysin, the number of hemolytic plaques and the NK cell activity of the mice in the high dose group are all increased, and the differences are all significant (q test, p is less than 0.05). The invention is proved to have the function of enhancing immunity.
The dendrobium officinale, radix ophiopogonis and American ginseng granules disclosed by the invention are used for carrying out toxicological safety experiments:
acute oral toxicity test in rats is as follows: using the maximum tolerated dose method, 10 samples were orally gavaged to challenge male and female rats (180-220g) at a dose of 16.0g/kg body weight. Weighing the sample to prepare 0.40g/mL, and performing two times of gavage administration at an interval of 4h according to the weight of 20 mL/kg. After the infection, the rats were observed for general condition, toxic symptoms and death for a period of two weeks. And (3) test results: the maximum dose of the sample for acute oral administration of male and female rats is more than 16.0g/kg body weight.
Acute oral toxicity testing in mice was as follows: using the maximum tolerated dose method, 10 male and female mice (18-22g) were each orally infected by gavage with a 16.0g/kg body weight dose of the sample. Weighing the sample to prepare 0.40g/mL, and performing two times of gavage administration at an interval of 4h according to the weight of 20 mL/kg. After the infection, the mice were observed for general condition, toxic symptoms and death for a period of two weeks. And (3) test results: the maximum dose of acute oral tolerance of the samples to male and female mice is more than 16.0g/kg body weight.
The micronucleus assay for mouse bone marrow cells was as follows: the samples are respectively taken as three dose groups of 2.0g/kg, 4.0g/kg and 8.0g/kg, and a negative control group (distilled water) and a positive control group (cyclophosphamide 60mg/kg body weight) are additionally arranged, 10 mice (25-30g, each half of male and female) in each group are taken as samples at intervals of 24 hours, the three dose groups are respectively called samples to be prepared into 0.1, 0.2 and 0.4g/mL, and the animals in each group are respectively subjected to intragastric administration according to the weight of 20 mL/kg. Once daily for 2 consecutive days. Animals were sacrificed 6h after the last sample, and their sternal bone marrow was sectioned, fixed with methanol, and stained with Giemsa. The micronucleus test result of the bone marrow cells of the sample is negative.
The teratospermia test was as follows: the samples were divided into three groups of 2.0g/kg, 4.0g/kg and 8.0g/kg body weight, and a negative control group (distilled water) and a positive control group (mitomycin C2.0 mg/kg body weight) were provided, each group containing 10 male mice (25-30 g). The three dosage groups are respectively weighed and sampled to be prepared into 0.1, 0.2 and 0.4g/mL, and the stomach of each group of animals is respectively irrigated according to the weight of 20 mL/kg. Once daily for 5 consecutive days. And on the 35 th day after the first sample giving, taking the epididymis on two sides, cutting into pieces, and taking the filtrate for preparing the slices. The number of teratomas of 1000 sperm per mouse was counted under microscopic observation. The sample has negative results of the teratospermia test.
Ames assay was as follows: selecting histidine auxotroph salmonella typhimurium TA97、TA98、TA100、TA102The plate incorporation method was used to test doses of 8. mu.g/dish, 40. mu.g/dish, 200. mu.g/dish, 1000. mu.g/dish, 5000. mu.g/dish. The number of recurrent colonies of each strain on the medium was counted directly. The detection is repeated once. The sample Ames test result is negative.
The 30 day feeding trial was as follows: the low, medium and high dose groups are respectively equivalent to 25, 50 and 100 times of the recommended dose of a human, and are orally administered to the rats by gavage for 30 days continuously. A blank control group was provided, and distilled water was given to the group for 30 days with free diet. Continuously observing for 30 days, recording body weight and food intake every week, calculating food utilization rate, performing hematology examination by taking blood from jugular vein at the end of test period, performing biochemical blood examination by cutting head and taking blood, performing general organ observation on each rat, weighing liver, kidney, spleen and testis (ovary), calculating viscera body ratio, and performing histopathology examination on liver, kidney, spleen, stomach, intestine and testis (ovary). As a result: the experimental animal has good growth condition, and has no obvious difference in hematology examination, biochemistry examination, main organ body ratio and histology examination result compared with the control group.
The results of the acute toxicity test, the micronucleus test, the teratospermia test, the Ames test and the 30-day feeding test show that the product is safe and nontoxic.
The stability test is as follows: three batches of samples are packaged according to the market and placed for 3 months under the conditions of 37-40 ℃ and 75% relative humidity, and the three batches of samples are respectively subjected to full-item detection (including sensory indexes, crude polysaccharide, total saponin, moisture, ash content, granularity, dissolubility, lead, arsenic, mercury, hexachloro-cyclohexane soprocide, dichlorodiphenyl trichloroethane, net content negative deviation, total bacterial count, coliform group, mould, saccharomycete, salmonella, shigella, staphylococcus aureus and beta hemolysis) in 0 month, 1 month, 2 months and 3 months, and detection results all accord with the specification of the product quality standard (enterprise standard).
The invention has the beneficial effects that: the dendrobium officinale, the radix ophiopogonis, the American ginseng, the astragalus membranaceus, the Chinese yam and the rhizoma polygonati are used as auxiliary materials, maltodextrin and xylitol are added to prepare the health-care food which is willing to be accepted by people, the formula is reasonable, the traditional Chinese medicine theory is met, and the modern pharmacology and clinical research basis is provided; the dendrobium officinale, radix ophiopogonis and American ginseng granules prepared by the invention have the function of enhancing immunity, are applicable to most people with low immunity caused by various physique inducers according to the theory of traditional Chinese medicine, and have good and wide market prospect.
Detailed Description
The formula of the dendrobium officinale, ophiopogon root and American ginseng granule comprises the following components: 10-40 parts of dendrobium officinale, 10-40 parts of radix ophiopogonis and 10-40 parts of American ginseng. In addition, any one or more of astragalus root 1-10 parts, Chinese yam 1-10 parts and sealwort 1-10 parts may be included.
The dendrobium officinale, ophiopogon root and American ginseng granules are prepared by the following processes:
(1) extracting dendrobium officinale: weighing the dendrobium officinale medicinal material according to a formula, putting the dendrobium officinale medicinal material into a multifunctional extraction tank, adding 30 times of water, heating to boil, preserving heat for 3 hours, filtering and pumping out liquid medicine; extracting for the second time, adding 30 times of water for extraction, boiling and keeping the temperature for 3 hours, filtering and pumping out the liquid medicine; extracting for the third time, adding 30 times of water for extraction, boiling, keeping the temperature for 3 hours, filtering, pumping out the liquid medicine, combining the three extracting solutions, and putting into a storage tank.
(2) Extracting other medicinal materials: weighing radix Ophiopogonis, radix Panacis Quinquefolii, radix astragali, rhizoma Dioscoreae, and rhizoma Polygonati according to formula, putting into a multifunctional extraction tank, adding 10 times of water, heating to boil, keeping the temperature for 2 hr, filtering, and pumping out the medicinal liquid; extracting for the second time, adding 10 times of water for extraction, boiling and keeping the temperature for 2 hours, filtering and pumping out the liquid medicine; mixing the two extractive solutions, and storing in a storage tank.
(3) Concentration: the extract was concentrated under reduced pressure to a relative density of about 1.05 (measured at 60 ℃).
(4) Boiling and granulating: and (3) taking maltodextrin and xylitol as auxiliary materials, spraying the extract, and performing boiling granulation to obtain the dendrobium officinale, ophiopogon root and American ginseng granules.
(5) Packaging: bagging and labeling according to the specified specification.
The following detailed description of specific embodiments of the invention
Example 1
Weighing 3500g of dendrobium officinale, putting into a multifunctional extraction tank, adding 30 times of water, heating to boil, keeping the temperature for 3 hours, filtering and pumping out liquid medicine; extracting for the second time, adding 30 times of water for extraction, boiling and keeping the temperature for 3 hours, filtering and pumping out the liquid medicine; extracting for the third time, adding 30 times of water for extraction, boiling, keeping the temperature for 3 hours, filtering, pumping out the liquid medicine, combining the three extracting solutions, and putting into a storage tank. Weighing 3500g of radix ophiopogonis and 3000g of American ginseng, putting the radix ophiopogonis and the American ginseng into a multifunctional extraction tank, adding 10 times of water, heating to boil, keeping the temperature for 2 hours, filtering and pumping out liquid medicine; extracting for the second time, adding 10 times of water for extraction, boiling and keeping the temperature for 2 hours, filtering and pumping out the liquid medicine; mixing the two extractive solutions, and storing in a storage tank. The extract was concentrated under reduced pressure to a relative density of about 1.05 (measured at 60 ℃). And (3) taking maltodextrin and xylitol as auxiliary materials, spraying the extract, and performing boiling granulation to obtain the lindera aggregata-iron sheet ginseng granules.
Results of the immune function test:
table 1: results of NK cell Activity and spleen lymphocyte transformation experiments
Note: compared with a control group, the significant difference is shown in table 1, and the NK cell activity of mice of each dose group of the dendrobium officinale, the radix ophiopogonis and the American ginseng granules has no significant difference compared with the control group; in the ConA-induced mouse spleen lymphocyte transformation experiment, the difference of OD of each dose group of samples is significantly different from that of a control group (p < 0.05).
Table 2: results of DTH, spleen index and thymus index experiments
Note: compared with the control group, the significant difference is shown in table 2, and the spleen index of the mice in the high-dose group of the dendrobium officinale, the radix ophiopogonis and the American ginseng granules is significantly different (p is less than 0.05) compared with the control group.
TABLE 3 phagocytosis of chicken erythrocytes by macrophages
| Group (g/kg) | Phagocytic index | Phagocytosis ratio (%) |
| Control group | 3.45±0.68 | 20.25±3.90 |
| 0.67 | 4.01±0.32 | 23.00±3.51 |
| 1.33 | 4.71±0.89* | 31.02±3.37* |
| 4.0 | 5.02±0.60* | 33.57±3.28* |
Note: significant differences compared to control group;
as shown in Table 3, the phagocytic percentage and phagocytic index of the medium and high dose groups of the granules of the invention have significant difference (p <0.05) compared with the control group.
According to the result, the product has the function of enhancing immunity.
The results of acute toxicity test, micronucleus test, sperm malformation test, Ames test and 30-day feeding test are all negative, and the product is safe and nontoxic.
The stability test results are as follows: the product has stable indexes and meets the quality standard.
Example 2
Weighing 3000g of dendrobium officinale, putting into a multifunctional extraction tank, adding 30 times of water, heating to boil, keeping the temperature for 3 hours, filtering and pumping out liquid medicine; extracting for the second time, adding 30 times of water for extraction, boiling and keeping the temperature for 3 hours, filtering and pumping out the liquid medicine; extracting for the third time, adding 30 times of water for extraction, boiling, keeping the temperature for 3 hours, filtering, pumping out the liquid medicine, combining the three extracting solutions, and putting into a storage tank. Weighing 3000g of radix ophiopogonis, 3000g of American ginseng and 1000g of astragalus mongholicus, putting the radix ophiopogonis, the American ginseng and the astragalus mongholicus into a multifunctional extraction tank, adding 10 times of water, heating to boil, keeping the temperature for 2 hours, filtering and pumping out liquid medicine; extracting for the second time, adding 10 times of water for extraction, boiling and keeping the temperature for 2 hours, filtering and pumping out the liquid medicine; mixing the two extractive solutions, and storing in a storage tank. The extract was concentrated under reduced pressure to a relative density of about 1.05 (measured at 60 ℃). And (3) taking maltodextrin and xylitol as auxiliary materials, spraying the extract, and performing boiling granulation to obtain the dendrobium officinale, ophiopogon root and American ginseng granules. Results of the immune function test:
table 6: results of NK cell Activity and spleen lymphocyte transformation experiments
Note: significant differences compared with the control group
As can be seen from table 6, the NK cell activity of mice of each dose group of the dendrobium officinale, ophiopogon japonicus and panax quinquefolius granules of the invention has no significant difference compared with the control group; in the ConA-induced mouse spleen lymphocyte transformation experiment, the difference of OD of each dose group of samples is significantly different from that of a control group (p < 0.05).
Table 7: results of DTH, spleen index and thymus index experiments
Note: significant differences compared with the control group
As can be seen from table 7, the spleen index of the mice in the high dose group of the dendrobium officinale, ophiopogon japonicus and panax quinquefolius granules of the invention is significantly different (p is less than 0.05) compared with the control group.
TABLE 8 phagocytosis of chicken erythrocytes by macrophages
| Group (g/kg) | Phagocytic index | Phagocytosis ratio (%) |
| Control group | 3.68±0.60 | 21.18±3.13 |
| 0.67 | 4.12±0.45 | 22.45±3.27 |
| 1.33 | 4.93±0.71* | 31.85±3.29* |
| 4.0 | 5.19±0.68* | 32.64±3.54* |
Note: significant differences compared to control group;
as shown in table 8, the phagocytic percentage and phagocytic index of the medium and high dose groups of the granules of the present invention were significantly different from those of the control group (p < 0.05).
According to the result, the product has the function of enhancing immunity.
The results of acute toxicity test, micronucleus test, sperm malformation test, Ames test and 30-day feeding test are all negative, and the product is safe and nontoxic.
The stability test results are as follows: the product has stable indexes and meets the quality standard.
Example 3
Weighing 3000g of dendrobium officinale, putting into a multifunctional extraction tank, adding 30 times of water, heating to boil, keeping the temperature for 3 hours, filtering and pumping out liquid medicine; extracting for the second time, adding 30 times of water for extraction, boiling and keeping the temperature for 3 hours, filtering and pumping out the liquid medicine; extracting for the third time, adding 30 times of water for extraction, boiling, keeping the temperature for 3 hours, filtering, pumping out the liquid medicine, combining the three extracting solutions, and putting into a storage tank. Weighing 2500g of radix ophiopogonis, 2500g of American ginseng, 1000g of astragalus mongholicus and 1000g of Chinese yam, putting the materials into a multifunctional extraction tank, adding 10 times of water, heating to boil, preserving heat for 2 hours, filtering and pumping out liquid medicine; extracting for the second time, adding 10 times of water for extraction, boiling and keeping the temperature for 2 hours, filtering and pumping out the liquid medicine; mixing the two extractive solutions, and storing in a storage tank. The extract was concentrated under reduced pressure to a relative density of about 1.05 (measured at 60 ℃). And (3) taking maltodextrin and xylitol as auxiliary materials, spraying the extract, and performing boiling granulation to obtain the dendrobium officinale, ophiopogon root and American ginseng granules.
Results of the immune function test:
table 11: results of NK cell Activity and spleen lymphocyte transformation experiments
Note: compared with a control group, the significant difference is shown in table 11, and the NK cell activity of the mice of each dose group of the dendrobium officinale, the radix ophiopogonis and the American ginseng granules has no significant difference compared with the control group; in the ConA-induced mouse spleen lymphocyte transformation experiment, the difference of OD of each dose group of samples is significantly different from that of a control group (p < 0.05).
Table 12: results of DTH, spleen index and thymus index experiments
Note: compared with the control group, the significant difference is shown in table 12, and the spleen index of the mice in the high-dose group of the dendrobium officinale, the radix ophiopogonis and the American ginseng granules is significantly different (p is less than 0.05) compared with the control group.
Table 13 experiment for phagocytosis of chicken red blood cells by macrophages
| Group (g/kg) | Phagocytic index | Phagocytosis ratio (%) |
| Control group | 3.34±0.68 | 20.09±3.51 |
| 0.67 | 3.89±0.54 | 22.58±3.75 |
| 1.33 | 4.68±0.79* | 31.87±3.81* |
| 4.0 | 4.99±0.68* | 32.58±3.69* |
Note: significant differences compared to control group;
as shown in table 13, the phagocytic percentage and phagocytic index of the medium and high dose groups of the granules of the present invention were significantly different from those of the control group (p < 0.05).
According to the result, the product has the function of enhancing immunity.
The results of acute toxicity test, micronucleus test, sperm malformation test, Ames test and 30-day feeding test are all negative, and the product is safe and nontoxic.
The stability test results are as follows: the product has stable indexes and meets the quality standard.
Example 4
Weighing 3000g of dendrobium officinale, putting into a multifunctional extraction tank, adding 30 times of water, heating to boil, keeping the temperature for 3 hours, filtering and pumping out liquid medicine; extracting for the second time, adding 30 times of water for extraction, boiling and keeping the temperature for 3 hours, filtering and pumping out the liquid medicine; extracting for the third time, adding 30 times of water for extraction, boiling, keeping the temperature for 3 hours, filtering, pumping out the liquid medicine, combining the three extracting solutions, and putting into a storage tank. Weighing 2500g of radix ophiopogonis, 2500g of American ginseng, 1000g of astragalus mongholicus and 1000g of rhizoma polygonati, putting the materials into a multifunctional extraction tank, adding 10 times of water, heating to boil, preserving heat for 2 hours, filtering and pumping out liquid medicine; extracting for the second time, adding 10 times of water for extraction, boiling and keeping the temperature for 2 hours, filtering and pumping out the liquid medicine; mixing the two extractive solutions, and storing in a storage tank. The extract was concentrated under reduced pressure to a relative density of about 1.05 (measured at 60 ℃). And (3) taking maltodextrin and xylitol as auxiliary materials, spraying the extract, and performing boiling granulation to obtain the dendrobium officinale, ophiopogon root and American ginseng granules.
Results of the immune function test:
table 16: NK thinResults of cell activity and spleen lymphocyte transformation experiments
Note: compared with a control group, the significant difference is shown in table 16, and the NK cell activity of the mice of each dose group of the dendrobium officinale, the radix ophiopogonis and the American ginseng granules has no significant difference compared with the control group; in the ConA-induced mouse spleen lymphocyte transformation experiment, the difference of OD of each dose group of samples is significantly different from that of a control group (p < 0.05).
Table 17: results of DTH, spleen index and thymus index experiments
Note: significant differences compared with the control group
As can be seen from table 17, the spleen index of the mice in the high dose group of the dendrobium officinale, ophiopogon japonicus and panax quinquefolius granules of the invention is significantly different (p <0.05) compared with the control group.
Table 18 macrophage phagocytosis of chicken erythrocytes experiment
| Group (g/kg) | Phagocytic index | Phagocytosis ratio (%) |
| Control group | 3.32±0.68 | 22.51±3.68 |
| 0.67 | 4.02±0.51 | 23.99±3.19 |
| 1.33 | 4.91±0.39* | 34.18±3.52* |
| 4.0 | 5.28±0.61* | 35.76±3.48* |
Note: significant differences compared to control group;
as can be seen from table 18, the phagocytic percentage and phagocytic index of the medium and high dose groups of the granules of dendrobium officinale, ophiopogon roots and panax quinquefolius of the present invention are significantly different (p <0.05) compared with the control group.
According to the result, the product has the function of enhancing immunity.
The results of acute toxicity test, micronucleus test, sperm malformation test, Ames test and 30-day feeding test are all negative, and the product is safe and nontoxic.
The stability test results are as follows: the product has stable indexes and meets the quality standard.
Survey of universality
The product prepared by the embodiment is randomly and freely delivered to 590 crowds according to the specification of 10 bags/bags and the consumption of 600 persons in one month, wherein the consumption covers all age stages and sexes; the specific data are as follows:
TABLE 19 age and gender numbers of the masses
| Man (name) | Woman (name) | |
| 18-25 years old | 3 | 2 |
| 26-35 years old | 16 | 8 |
| 36-45 years old | 64 | 35 |
| 46-55 years old | 113 | 168 |
| 56-65 years old | 78 | 91 |
| Over 65 years old | 2 | 10 |
(all the people have the explanation, the product is a sample produced by the company in an experiment and has the function of enhancing immunity, and if discomfort or adverse reaction exists, the patient should stop taking the product in time)
After one month, the taking is finished, and 581 parts of effective feedback are received, wherein the samples represent definite effective 563 parts and 18 parts of feedback without obvious effect, and the samples are concentrated in 18-35 years old and mostly male; there was no adverse or uncomfortable reaction feedback.
According to results, the product has definite function of enhancing immunity and no safety problem, and can obtain better economic and social benefits when being developed into health-care food.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. The invention is limited only by the claims and their full scope and equivalents.
Claims (8)
1. The dendrobium officinale, radix ophiopogonis and American ginseng granules are characterized in that the prescription consists of the following components: 10-40 parts of dendrobium officinale, 10-40 parts of radix ophiopogonis and 10-40 parts of American ginseng.
2. The dendrobium officinale, radix ophiopogonis and American ginseng granule as claimed in claim 1, further comprising 1-10 parts by mass of radix astragali.
3. The dendrobium officinale, radix ophiopogonis and American ginseng granule as claimed in claim 2, further comprising 1-10 parts by mass of Chinese yam.
4. The granule of claim 2, further comprising 1-10 parts by mass of rhizoma Polygonati.
5. The dendrobium officinale, radix ophiopogonis and American ginseng granule as claimed in claim 1, further comprising 1-10 parts by mass of Chinese yam.
6. The granule of claim 5, further comprising 1-10 parts by mass of rhizoma Polygonati.
7. The granule of claim 6, further comprising radix astragali in an amount of 1-10 parts by mass.
8. The granule of claim 1, further comprising 1-10 parts by mass of rhizoma Polygonati.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010834915.8A CN112021566A (en) | 2020-08-24 | 2020-08-24 | Dendrobium officinale, American ginseng and radix ophiopogonis granules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010834915.8A CN112021566A (en) | 2020-08-24 | 2020-08-24 | Dendrobium officinale, American ginseng and radix ophiopogonis granules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112021566A true CN112021566A (en) | 2020-12-04 |
Family
ID=73576906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010834915.8A Pending CN112021566A (en) | 2020-08-24 | 2020-08-24 | Dendrobium officinale, American ginseng and radix ophiopogonis granules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112021566A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115607628A (en) * | 2022-10-20 | 2023-01-17 | 浙江长典药物技术开发有限公司 | Dendrobium candicum fluid extract, preparation process and equipment thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138526A (en) * | 2014-08-03 | 2014-11-12 | 浙江红石梁集团天台山乌药有限公司 | Granules prepared by combined spicebush roots, dendrobium candidum and ginseng |
| CN105250729A (en) * | 2015-11-18 | 2016-01-20 | 浙江森宇有限公司 | Dendrobium officinale electuary and preparing method thereof |
| US20170274008A1 (en) * | 2016-03-24 | 2017-09-28 | Hong Kong Baptist University | Use of polysaccharide in Dendrobium officinale for anti-fatigue |
| CN107625892A (en) * | 2017-09-29 | 2018-01-26 | 南京仙草堂生物科技有限公司 | A kind of Chinese medicine preparation based on dendrobium candidum |
| CN109198639A (en) * | 2018-09-26 | 2019-01-15 | 湖北省医药工业研究院有限公司 | A kind of composition for immunological enhancement containing the lactobacillus and its preparation method and application |
-
2020
- 2020-08-24 CN CN202010834915.8A patent/CN112021566A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138526A (en) * | 2014-08-03 | 2014-11-12 | 浙江红石梁集团天台山乌药有限公司 | Granules prepared by combined spicebush roots, dendrobium candidum and ginseng |
| CN105250729A (en) * | 2015-11-18 | 2016-01-20 | 浙江森宇有限公司 | Dendrobium officinale electuary and preparing method thereof |
| US20170274008A1 (en) * | 2016-03-24 | 2017-09-28 | Hong Kong Baptist University | Use of polysaccharide in Dendrobium officinale for anti-fatigue |
| CN107625892A (en) * | 2017-09-29 | 2018-01-26 | 南京仙草堂生物科技有限公司 | A kind of Chinese medicine preparation based on dendrobium candidum |
| CN109198639A (en) * | 2018-09-26 | 2019-01-15 | 湖北省医药工业研究院有限公司 | A kind of composition for immunological enhancement containing the lactobacillus and its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| 安好义: "《中药材质量新说》", 31 January 2019, 四川科学技术出版社 * |
| 邵国杰: "《神奇本草》", 31 May 2019, 中国中医药出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115607628A (en) * | 2022-10-20 | 2023-01-17 | 浙江长典药物技术开发有限公司 | Dendrobium candicum fluid extract, preparation process and equipment thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104547826B (en) | Galangal rhizome extract treats the medical usage of dysmenorrhoea | |
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN104138526B (en) | A kind of root of three-nerved spicebush iron sheet ginseng granules agent | |
| CN108785422B (en) | Traditional Chinese medicine composition for treating acute mastitis and preparation method thereof | |
| CN114246878B (en) | Traditional Chinese medicine extract composition and preparation method and application thereof | |
| CN105168811A (en) | Traditional Chinese medicine soluble powder for controlling infectious proventriculitis and ventriculitis in broiler chicken and preparation method thereof | |
| CN112021566A (en) | Dendrobium officinale, American ginseng and radix ophiopogonis granules | |
| JP2002275086A (en) | Composition for improving valetudinarianish | |
| CN101209296A (en) | Chinese medicinal granule with worm-expelling liver-caring, hemostasis and dysentery-stopping efficacy | |
| CN1135918C (en) | Method for increasing farrowing amount of sow | |
| CN113476562B (en) | Composition and preparation method and application thereof | |
| CN113577187B (en) | Traditional Chinese medicine composition and traditional Chinese medicine extract for treating influenza and preparation method and application thereof | |
| CN104524167A (en) | Traditional Chinese medicine preparation for treating liver cirrhosis and liver ascites and preparation method of traditional Chinese medicine preparation | |
| CN108404088B (en) | Traditional Chinese medicine for treating type II diabetes and preparation method thereof | |
| JPH11158077A (en) | Composition having alleviating effect on stress | |
| CN111298020A (en) | Traditional Chinese medicine composition with anti-fatigue effect and preparation method and application thereof | |
| CN112439030A (en) | Medicine for quickly reducing uric acid | |
| CN109758559A (en) | A kind of Chinese medicine composition and its preparation method and application for treating chronic fatigue syndrome | |
| CN114028531B (en) | Medicine for treating breast cancer and preparation method and application thereof | |
| CN106511881B (en) | A Chinese medicinal composition for invigorating kidney and preventing miscarriage, and its preparation method | |
| CN103316103A (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
| CN117018125B (en) | Anti-fatigue pharmaceutical composition | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN115737762B (en) | A pharmaceutical composition with memory improving and brain health and cognitive function protecting effects | |
| CN112807362B (en) | Traditional Chinese medicine composition for treating subacute thyroiditis in acute stage and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201204 |